PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

• Published in: Cancer treatment reviews Vol. 41; no. 2; pp. 114 - 121
• Main Authors: Massari, F, Santoni, M, Ciccarese, C, Santini, D, Alfieri, S, Martignoni, G, Brunelli, M, Piva, F, Berardi, R, Montironi, R, Porta, C, Cascinu, S, Tortora, G
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2015
• Subjects: Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antibody-Dependent Cell Cytotoxicity - drug effects; Antineoplastic Agents - immunology; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - metabolism; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - immunology; Carcinoma, Renal Cell - pathology; Cell Proliferation - drug effects; Clinical Trials as Topic; Down-Regulation; Gene Expression Regulation, Neoplastic; Hematology, Oncology and Palliative Medicine; Humans; Immunotherapy; Immunotherapy - methods; Ipilimumab; Kidney Neoplasms - drug therapy; Kidney Neoplasms - immunology; Kidney Neoplasms - pathology; Neoplasm Grading; Neoplasm Staging; PD-1; PDL-1; Prognosis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - metabolism; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors; Renal cell carcinoma; Signal Transduction - drug effects; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Vascular Endothelial Growth Factor A - antagonists & inhibitors; PDL-1; Renal cell carcinoma; PD-1; Immunotherapy
• ISSN: 0305-7372; 1532-1967
• DOI: 10.1016/j.ctrv.2014.12.013

Highlights • Evasion of immune surveillance, a process defined immune-editing, leads to RCC malignant progression. • The PD-1/PD-L1 axis inhibition by targeted-antibodies, increases T-cell proliferation and anti-tumor activity. • PD-1 and PD-L1 inhibitors have been tested in RCC, alone or combined with anti-VEGF/VEGFR drugs or other immunotherapies. • We discuss the role of PD-1/PD-L1 in RCC, focusing on current clinical studies and future perspectives.